FDA Extends Decision Date for AstraZeneca's Camizestrant in HR-positive Breast Cancer
The FDA has extended the PDUFA date for camizestrant to allow for additional data review related to its NDA.
Indication
Clinical and regulatory intelligence for Hormone Receptor-positive Breast Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.